UBS Analyst Cautions That Bigger Rivals Could Hurt Bruker's Mass Spec Business | GenomeWeb
Three weeks after Bruker Biosciences said a rebound in its mass spectrometry division helped the company post a 9-percent increase in total revenue during its second quarter, a research note by an investment bank analyst cautioned that the company’s mass-spec business could be hurt by bigger competitors.
 
The note by UBS analyst Derik De Bruin came as the investment firm downgraded Bruker’s stock to “neutral” from “buy” while maintaining a $7 target price on the shares.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.